bluebird bio (BLUE) Granted FDA Priority Review of Biologics License Application for eli-cel Gene Therapy

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

If approved, eli-cel will be the first and only gene therapy for the treatment of CALD, a rare neurodegenerative disease primarily affecting young children that can lead to progressive, irreversible loss of neurologic function and death

FDA set PDUFA date of June 17, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc.... More